PTUPB Compound Potentiates Cisplatin-Based-First Line Therapies with No Additional Toxicity
Orally bioavailableSignificantly reduced tumor growth compared with inhibitors selective to either pathway, alone and in combinationProlonged survival, with no additional toxicity
Cisplatin-Based-First Line TherapiesCancer
Cisplatin-based therapies, despite their toxicity, are used to treat most cancers due to their moderate effectiveness. Cisplatin-based-first line therapies, such as combination gemcitabine and cisplatin (GC), are often used due to higher response rates, however have associated increased toxicities. There is a need for more effective therapies that do not have higher levels of toxicity. Researchers at the University of California, Davis have discovered a compound, PTUPB, that inhibits COX-2 and sEH and protects normal tissues from cisplatin toxicity during treatment. The compound was successfully tested in patient-derived xenograft mouse models to potentiate cisplatin and GC therapies, resulting in significantly reduced tumor growth compared with inhibitors selective to either pathway, either as single agents or in combination. The models also showed prolonged survival, with no additional toxicity compared to cisplatin alone. This makes PTUPB an attractive agent for further development as a combination chemotherapy compound.
Related Materials Zhang, Guodong et al. “Dual Inhibition of Cyclooxygenase-2 and Soluble Epoxide Hydrolase Synergistically Suppresses Primary Tumor Growth and Metastasis.” Proceedings of the National Academy of Sciences of the United States of America 111.30 (2014): 11127–11132. doi: 10.1073/pnas.1410432111. Additional Technologies by these Inventors Tech ID/UC Case 29314/2017-956-0 Related Cases 2017-956-0
Wang, Fuli et al. “COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.” Molecular Cancer Therapeutics. 17.2(2018):474-483. doi: 10.1158/1535-7163.MCT-16-0818.
美國
